Teva Raises 2026 Revenue Outlook as Three Brands’ Combined Sales Gain 33%
Photo: TokenPost
Teva Pharmaceutical Industries raised its 2026 revenue outlook Tuesday after combined third-quarter sales from AUSTEDO, AJOVY and UZEDY grew 33% in local currency to about $1.1 billion. The company lifted its full-year revenue range to $16.7 billion to $17 billion, from $16.5 billion to $16.85 billion. The quarter ended Sept. 30. AUSTEDO generated $751 million in third-quarter revenue, up 21% year over year. AJOVY brought in $269 million, up 61%, while UZEDY generated $85 million, up 96%. Teva also raised its 2026 revenue forecasts for all three brands.
Source: TokenPost
